Abstract
Objective: To evaluate the use of low-dose computed tomography (TCBD) in the screening of lung cancer (CP). Bibliographic review: PC represents the neoplasm with the highest incidence and mortality in the world and is characterized by rapid progression and late diagnosis, factors that limit therapeutic options and contribute to low patient survival. Screening measures are favorable in asymptomatic patients at high risk of cancer, contributing to a favorable prognosis. TCBD proves to be the main screening tool, presenting greater sensitivity in the early detection of lung cancer and stage I cancer, when compared to screening by chest radiography. However, factors such as the cost-benefit ratio, high exposure to ionizing radiation and risk of false positives represent obstacles that must be analyzed and considered before the implementation of generalized screening by TCBD. Final considerations: TCBD is the object of study due to the great relevance of its use in screening for lung cancer, resulting from bibliographic analyzes and previous research.